Fig. 1: Use of imaging mass cytometry (IMC) for identification of neuronal and glial subtypes in human post-mortem brain. | Nature Communications

Fig. 1: Use of imaging mass cytometry (IMC) for identification of neuronal and glial subtypes in human post-mortem brain.

From: Intracellular accumulation of amyloid-ß is a marker of selective neuronal vulnerability in Alzheimer’s disease

Fig. 1

a FFPE sections of MTG from 12 non-disease controls and 31 AD cases were processed for IMC. Depending on the analysis, samples were divided based on expression of TREM2 common allele (CV) or TREM2 risk variants (R62H and R47H) and Braak stages. b List of candidate neuronal markers tested in developing the IMC antibody panel with their expected cortical distributions in middle temporal gyrus (MTG), prefrontal cortex (PFC), and entorhinal cortex (EC) layer II, previous associations with neuronal vulnerability, and corresponding references. Antibodies included in the final panel are indicated in red. c Example of IMC images obtained from one region of interest (ROI) processed with the final antibody panel. Each ROI ablated spans the entire thickness of the neocortex cortex (L1-L6). d A cartoon illustrating the full methodological pipeline from antibody testing (first by immunofluorescence microscopy [IF] and then using IMC), staining and ablation of full sample cohort, automated image analysis using SIMPLI (see Methods) to final data analysis in R. Graphics were created in BioRender (Caramello, A. (2025) https://BioRender.com/z22okvn)103. Scale bars in c represent 100 μm.

Back to article page